The FDA database lists a supplement dated 14 October 2026 to the biologics licence for etanercept (ENBREL), held by Immunex. The record gives no new indication or safety information, and supplements of this kind usually concern labelling or manufacturing.
The relevance for gastroenterologists is indirect. Etanercept is not effective for inflammatory bowel disease, unlike other TNF inhibitors, and new-onset or worsening IBD has been reported during etanercept treatment for rheumatic disease.
Patients referred with new bowel symptoms while on etanercept deserve a careful look rather than reassurance.
- Treat this as an administrative change unless FDA publishes details
- Do not use etanercept for Crohn disease or ulcerative colitis
- Investigate new diarrhoea or rectal bleeding in patients on etanercept
- Liaise with the rheumatologist about switching TNF inhibitor if IBD develops
Why it matters
It changes nothing in itself, but etanercept-associated IBD is easy to miss.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free